CPMD Stock Overview
CannaPharmaRX, Inc. evaluates, negotiates, acquires, and develops various cannabis cultivation projects in Canada. More details
| Snowflake Score | |
|---|---|
| Valuation | 2/6 |
| Future Growth | 0/6 |
| Past Performance | 2/6 |
| Financial Health | 0/6 |
| Dividends | 0/6 |
CannaPharmaRX, Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$0.0094 |
| 52 Week High | US$0.028 |
| 52 Week Low | US$0.0001 |
| Beta | -1250.88 |
| 11 Month Change | -4.08% |
| 3 Month Change | -1.05% |
| 1 Year Change | 56.67% |
| 33 Year Change | -57.66% |
| 5 Year Change | -99.41% |
| Change since IPO | -100.00% |
Recent News & Updates
Recent updates
Shareholder Returns
| CPMD | US Pharmaceuticals | US Market | |
|---|---|---|---|
| 7D | 10.6% | -5.3% | -1.2% |
| 1Y | 56.7% | 8.7% | 30.4% |
Return vs Industry: CPMD exceeded the US Pharmaceuticals industry which returned 8.5% over the past year.
Return vs Market: CPMD exceeded the US Market which returned 29.7% over the past year.
Price Volatility
| CPMD volatility | |
|---|---|
| CPMD Average Weekly Movement | 34.6% |
| Pharmaceuticals Industry Average Movement | 9.4% |
| Market Average Movement | 6.2% |
| 10% most volatile stocks in US Market | 15.5% |
| 10% least volatile stocks in US Market | 3.1% |
Stable Share Price: CPMD's share price has been volatile over the past 3 months compared to the US market.
Volatility Over Time: CPMD's weekly volatility has decreased from 52% to 35% over the past year, but is still higher than 75% of US stocks.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| n/a | 21 | n/a | www.cannapharmarx.com |
CannaPharmaRX, Inc. evaluates, negotiates, acquires, and develops various cannabis cultivation projects in Canada. The company is based in Calgary, Canada.
CannaPharmaRX, Inc. Fundamentals Summary
| CPMD fundamental statistics | |
|---|---|
| Market cap | US$6.17m |
| Earnings (TTM) | US$1.38m |
| Revenue (TTM) | US$338.00k |
4.5x
P/E Ratio18.3x
P/S RatioIs CPMD overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| CPMD income statement (TTM) | |
|---|---|
| Revenue | US$338.00k |
| Cost of Revenue | US$1.65m |
| Gross Profit | -US$1.31m |
| Other Expenses | -US$2.69m |
| Earnings | US$1.38m |
Last Reported Earnings
Sep 30, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | 0.0021 |
| Gross Margin | -387.45% |
| Net Profit Margin | 408.29% |
| Debt/Equity Ratio | -51.0% |
How did CPMD perform over the long term?
See historical performance and comparison